Journal
NATURE MEDICINE
Volume 26, Issue 7, Pages 1041-+Publisher
NATURE RESEARCH
DOI: 10.1038/s41591-020-0933-1
Keywords
-
Funding
- Claudia Adams Barr Program for Innovative Cancer Research
- DFCI Medical Oncology grant award
- H.L. Snyder Medical Research Foundation
- British Colombia Children's Hospital Research Institute (BCCHRI) Investigator Grant Award Program
- BCCHRI Establishment Award
- Provincial Health Services Authority
- Children's & Women's Health Centre of BC
- BC Children's Hospital Foundation
- Canadian Institutes of Health Research (CIHR) Banting Fellowship
Ask authors/readers for more resources
A cell-free DNA-methylation sequencing assay accurately identifies renal cell carcinoma using plasma and urine samples. Improving early cancer detection has the potential to substantially reduce cancer-related mortality. Cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) is a highly sensitive assay capable of detecting early-stage tumors. We report accurate classification of patients across all stages of renal cell carcinoma (RCC) in plasma (area under the receiver operating characteristic (AUROC) curve of 0.99) and demonstrate the validity of this assay to identify patients with RCC using urine cell-free DNA (cfDNA; AUROC of 0.86).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
